Calton & Associates Inc. Invests $585,000 in Bristol-Myers Squibb (NYSE:BMY)

Calton & Associates Inc. bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,786 shares of the biopharmaceutical company’s stock, valued at approximately $585,000.

Other institutional investors also recently made changes to their positions in the company. Northwest Financial Advisors bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $34,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $40,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $40,000. Finally, Fairman Group LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $42,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.02 during trading hours on Friday, hitting $41.53. 19,547,917 shares of the company’s stock were exchanged, compared to its average volume of 15,754,717. Bristol-Myers Squibb has a fifty-two week low of $39.63 and a fifty-two week high of $65.38. The firm has a 50 day moving average of $42.97 and a two-hundred day moving average of $48.16. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The firm has a market cap of $84.19 billion, a P/E ratio of -13.40, a P/E/G ratio of 14.54 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 earnings per share. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.